Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 19 December 2024

Residuum: This phase III trial is comparing lenalidomide (a type of chemotherapy) consolidation versus no consolidation in patients with Chronic Lymphocytic Leukaemia (CLL)An Australasian, Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation versus No Consolidation in Patients With Chronic Lymphocytic Leukaemia and Residual Disease Following Induction Chemotherapy (CLL6)

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People18 - 75

Trial acronym

Residuum

Clinical summary

Summary

The research project is trying to find out if we can improve the results of best available chemotherapy for Chronic Lymphocytic Leukaemia (CLL) by the addition of a new drug called lenalidomide.

Conditions

This trial is treating people with Chronic Lymphocytic Leukaemia

Eligibility

Inclusion

  • Confirmed relapsed and advanced chronic lymphocytic leukemia (CLL)

    • Binet stage B or C disease with rapid disease progression, enlarged lymph nodes and organs, or severe B-symptoms
  • No prior non-response to fludarabine combination therapy

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-3
  • Life expectancy > 6 months
  • No severe organ dysfunction
  • No other prior or concurrent neoplasm, autoimmune hemolytic anemia, or thrombocytopenia

PRIOR CONCURRENT THERAPY:

  • No more than three previous treatment regimens for CLL (fludarabine allowed)

Inclusion

  • You have had a certain type of treatment or surgical procedure.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR, ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Australasian Leukaemia and Lymphoma Group (ALLG)

Scientific Title

An Australasian, Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation versus No Consolidation in Patients With Chronic Lymphocytic Leukaemia and Residual Disease Following Induction Chemotherapy (CLL6)

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information